Avoiding Liver Biopsies

Two words: Biopsy Avoidance.

Here’s a summary of the Gastroenterology & Endoscopy News article “In Lieu of Biopsy: A Review of Noninvasive Liver Disease Assessments” (posted August 28, 2025):

---

Overview

• Purpose: The article reviews noninvasive liver disease assessments (NILDAs)—both blood-based and imaging-based—to evaluate fibrosis, steatosis, and portal hypertension in chronic liver disease (CLD) as alternatives to invasive liver biopsy.
• Rationale: Advanced fibrosis (F3) and cirrhosis (F4) are key thresholds where liver-related morbidity and mortality significantly increase. Early and accurate staging is critical for effective management of conditions like HBV, HCV, and MASLD.

---

Types of NILDAs

• Blood-Based Tests:
  • Simple, nonproprietary: APRI, FIB-4, NAFLD Fibrosis Score (NFS)
  • Proprietary / complex: FibroTest/FibroSURE, FibroMeter, ELF, Hepascore, OWLiver, FibroSpec II, Easy Liver Fibrosis Test
    These rely on routine lab values plus additional markers for complex scores.
• Imaging-Based Techniques:
  • VCTE (vibration-controlled transient elastography)
  • SWE (shear-wave elastography)
  • MRE (magnetic resonance elastography)
    These assess liver stiffness and can also quantify steatosis, offering a more comprehensive evaluation.

---

Guidance from 2025 AASLD Guidelines

• Initial Screening: Use simple blood tests (e.g., FIB‑4, APRI) rather than costly proprietary ones.
• Performance Metrics:
  • FIB-4:
    • HCV: Cutoffs of 1.45 (sensitivity ~86%, specificity ~70%) and 3.25 (sensitivity ~55%, specificity ~90%) for advanced fibrosis.
    • HBV and MASLD have similar performance patterns, though sensitivity may vary.
      
  • NFS for MASLD: Good at ruling out (sensitivity ~0.75, cutoff < –1.455) and ruling in (specificity ~0.96, cutoff > 0.676), though ~33% of results fall into indeterminate range.
    
• Imaging Tests Superiority:
  • Imaging methods offer higher sensitivity and specificity for detecting advanced fibrosis and cirrhosis across different etiologies.
  • Example: MRE shows nearly perfect (1.0) sensitivity and specificity in HBV; VCTE and SWE also perform strongly.
    
• Choosing the Right Test:
  • Choose imaging based on availability (e.g., VCTE is the most accessible), patient factors (obesity, ascites), and clinical needs (e.g., cross-sectional imaging advantage of MRE).
  • Obesity or high liver enzymes may reduce accuracy—XL probe options or MRE may be preferred.
    
• Sequential Strategy Recommended:
  • A stepwise approach—blood-based test followed by imaging, when indicated—improves accuracy and reduces unnecessary biopsies. This is already reflected in MASLD management recommendations.

---

Key Considerations

• NILDAs are strong at identifying extremes (no fibrosis or cirrhosis); staging moderate fibrosis (e.g., F2 vs F3) remains challenging.
• Many tests yield indeterminate results, necessitating further evaluation or biopsy.
• Not suitable for longitudinal monitoring—NILDAs should not replace biopsies for tracking fibrosis regression or progression.
• Steatosis assessment: Imaging-based methods like TE-CAP (transient elastography) and MRI-PDFF outperform blood-based tests for fat quantification.
• Practical challenges include limited access to imaging, operator dependence, and lack of robust data in pediatric or post-treatment populations.

---

The Net Net

The article highlights a robust, guideline-driven framework for noninvasive liver evaluation:

1. Start with simple blood-based tests (like FIB‑4 or APRI) to screen for advanced fibrosis.
2. Use imaging-based tests (VCTE, SWE, or MRE) for more definitive staging where available.
3. Reserve liver biopsy for cases when noninvasive tests are indeterminate or when precise histology is required.
4. Steatosis is better assessed via imaging modalities.
5. Longitudinal tracking of liver fibrosis still lacks reliable noninvasive options.

This approach significantly reduces reliance on liver biopsy and enhances accessibility for both specialists and general clinicians in managing chronic liver disease.

Table 1. Available Biomarkers for the Evaluation of Fibrosis in CLD
Blood-Based		Imaging-Based
Simple, Nonproprietary	Complex, Proprietary
APRI	FibroTest/FibroSURE	VCTE
FIB-4 index	FibroSpec II	Acoustical radial force imaging
NFS	Hepascore	SWE MRE
FibroIndex	FibroMeter
King’s Score	ELF
Easy Liver Fibrosis Test	OWLiver
APRI, aspartate platelet ratio index; CLD, chronic liver disease; ELF, Enhanced Liver Fibrosis; FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; SWE, shear wave elastography; VCTE, vibration-controlled transient elastography.